Tracy Yen-Lin Driver, MD
Internal Medicine · Long Beach
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Healthcare Partners Affiliates Medical Group · 775 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Driver’s office at (562) 426-3333 to ask if they take your plan before you enroll.
California Medical Board record
Licence A133863 · Current
Licensed to practise in California · since 2014 · expires 2028-09-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$10,756
Medicare paid this office $10,756 for 46 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 30 | $5,200 | $91 |
| Short return visit (20+ min) | 15 | $1,645 | $72 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $64 | None |
Who their Medicare patients are
46 Original Medicare patients in 2024. Average age 70 · Also on Medicaid 74% · Health risk score 1.32. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 70% · Diabetes 50% · Chronic kidney disease 30% · Depression 26%.
The office billed $43,314, Medicare allowed $16,119 and paid $10,756; for 304 services of 15 kinds; $64 of it was for drugs given in the office and $10,692 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 46 | 304 | 70 | 1.32 | $43,314 | $10,756 |
| 2023 | 32 | 165 | 69 | 1.53 | $18,254 | $8,672 |
| 2022 | 22 | 111 | 72 | 2.45 | $10,768 | $5,293 |
| 2021 | 45 | 213 | 72 | 1.31 | $14,615 | $7,876 |
| 2020 | 41 | 218 | 72 | 1.70 | $17,978 | $7,807 |
| 2019 | 33 | 237 | 73 | 1.79 | $45,869 | $10,910 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 20 | $5,369 | $103 |
| Short return visit (20+ min) | 14 | $1,646 | $72 |
2022: 1 service
| Return visit (30+ min) | 16 | $3,140 | $101 |
2021: 4 services
| Return visit (30+ min) | 14 | $2,413 | $115 |
| Aspiration and/or injection of fluid from large joint | 16 | $1,341 | $56 |
| Short return visit (20+ min) | 11 | $893 | $74 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 18 | $121 | None |
2020: 3 services
| Return visit (30+ min) | 16 | $1,648 | $75 |
| Telephone medical discussion with physician, 5-10 minutes | 22 | $1,292 | $36 |
| Short return visit (20+ min) | 20 | $1,212 | $48 |
2019: 2 services
| Return visit (30+ min) | 12 | $1,436 | $96 |
| Short return visit (20+ min) | 17 | $1,169 | $65 |
Medicaid work
$13,542 in 2024
Medicaid paid $13,542 for 862 billed services this clinician did in 2024, up to 54 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 496 | $7,329 |
| New patient visit (30+ min) | 101 | $2,293 |
| Short return visit (20+ min) | 162 | $1,974 |
| New patient visit (45+ min) | 90 | $1,812 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $134 |
| 2024 | 862 | 5 | 54 | $13,542 |
| 2023 | 552 | 4 | 35 | $54,894 |
| 2022 | 455 | 4 | 33 | $38,955 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 297 | $33,395 |
| New patient visit (45+ min) | 106 | $12,797 |
| New patient visit (30+ min) | 63 | $4,559 |
| Short return visit (20+ min) | 86 | $4,144 |
2022
| Return visit (30+ min) | 253 | $24,564 |
| New patient visit (45+ min) | 175 | $13,272 |
| New patient visit (30+ min) | 14 | $787 |
| Short return visit (20+ min) | 13 | $332 |
Drugs they prescribed that Part D paid
$2,492,040
Pharmacies billed $2,492,040 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
956 generic and 368 brand-name prescriptions · $2,492,040 in drug cost · 12 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 130 | $1,226,719 | $9,436 |
| Enbrel Sureclick | 60 | $469,355 | $7,823 |
| Actemra Actpen | 23 | $98,784 | $4,295 |
| Humira | 14 | $91,102 | $6,507 |
| Kevzara | 13 | $56,200 | $4,323 |
See all 23 drugs
| Humira(Cf) | 130 | $1,226,719 | $9,436 |
| Enbrel Sureclick | 60 | $469,355 | $7,823 |
| Actemra Actpen | 23 | $98,784 | $4,295 |
| Humira | 14 | $91,102 | $6,507 |
| Kevzara | 13 | $56,200 | $4,323 |
| Prolia | 31 | $52,858 | $1,705 |
| Hydroxychloroquine Sulfate | 200 | $7,752 | $39 |
| Leflunomide | 54 | $5,049 | $93 |
| Methotrexate | 167 | $4,216 | $25 |
| Mycophenolate Mofetil | 30 | $3,154 | $105 |
| Sulfasalazine | 65 | $3,110 | $48 |
| Azathioprine | 14 | $1,516 | $108 |
| Pilocarpine | 11 | $1,293 | $118 |
| Prednisone | 125 | $1,091 | $9 |
| Celecoxib | 17 | $746 | $44 |
| Diclofenac | 18 | $455 | $25 |
| Alendronate | 59 | $317 | $5 |
| Gabapentin | 15 | $292 | $19 |
| Folic Acid | 42 | $275 | $7 |
| Allopurinol | 15 | $170 | $11 |
| Duloxetine | 12 | $149 | $12 |
| Naproxen | 12 | $119 | $10 |
| Meloxicam | 27 | $53 | $2 |
Year by year
| 2024 | 1,324 | 247 | None | 28% | $2,492,040 |
| 2023 | 1,666 | 284 | 2% (37) | 23% | $2,311,868 |
| 2022 | 1,350 | 288 | 1% (17) | 19% | $1,466,546 |
| 2021 | 749 | 220 | None | 15% | $583,835 |
| 2020 | 1,096 | 192 | 2% (16) | None | $642,703 |
| 2019 | 474 | 188 | None | 34% | $407,832 |
| 2018 | 98 | 32 | None | 38% | $126,204 |
| 2017 | 45 | 16 | None | 33% | $21,373 |
| 2016 | 15 | None | None | None | $1,583 |
| 2015 | 25 | 12 | None | None | $16,428 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Humira(Cf) | 114 | $1,023,328 | $8,977 |
| Enbrel Sureclick | 48 | $382,455 | $7,968 |
| Enbrel | 22 | $178,009 | $8,091 |
| Xeljanz Xr | 25 | $155,662 | $6,226 |
| Humira | 13 | $96,294 | $7,407 |
| Actemra Actpen | 19 | $92,651 | $4,876 |
| Orencia | 16 | $75,759 | $4,735 |
| Prolia | 40 | $66,519 | $1,663 |
| Hydroxychloroquine Sulfate | 237 | $17,858 | $75 |
| Methotrexate | 210 | $10,041 | $48 |
| Leflunomide | 72 | $8,449 | $117 |
| Sulfasalazine | 77 | $4,682 | $61 |
| Mycophenolate Mofetil | 26 | $3,009 | $116 |
| Prednisone | 212 | $2,813 | $13 |
| Rifampin | 23 | $1,055 | $46 |
| Allopurinol | 57 | $1,014 | $18 |
| Gabapentin | 27 | $816 | $30 |
| Etodolac | 13 | $773 | $59 |
| Alendronate | 55 | $596 | $11 |
| Diclofenac | 25 | $558 | $22 |
| Celecoxib | 20 | $357 | $18 |
| Naproxen | 22 | $292 | $13 |
| Hydrocodone-Acetaminophen | 16 | $249 | $16 |
| Folic Acid | 40 | $198 | $5 |
| Amlodipine Besylate | 17 | $197 | $12 |
| Cyclobenzaprine | 20 | $156 | $8 |
| Meloxicam | 15 | $113 | $8 |
| Ibuprofen | 13 | $111 | $9 |
| Tramadol | 18 | $77 | $4 |
2022: 21 drugs
| Enbrel Sureclick | 60 | $451,116 | $7,519 |
| Humira(Cf) | 42 | $323,951 | $7,713 |
| Xeljanz Xr | 25 | $135,972 | $5,439 |
| Humira | 14 | $95,547 | $6,825 |
| Enbrel | 13 | $89,086 | $6,853 |
| Remicade | 15 | $56,392 | $3,759 |
| Prolia | 26 | $38,318 | $1,474 |
| Hydroxychloroquine Sulfate | 168 | $12,034 | $72 |
| Methotrexate | 173 | $9,269 | $54 |
| Leflunomide | 41 | $7,100 | $173 |
| Prednisone | 282 | $4,255 | $15 |
| Sulfasalazine | 62 | $2,398 | $39 |
| Colchicine | 12 | $2,174 | $181 |
| Allopurinol | 65 | $1,191 | $18 |
| Etodolac | 13 | $889 | $68 |
| Gabapentin | 42 | $829 | $20 |
| Diclofenac | 27 | $681 | $25 |
| Alendronate | 32 | $525 | $16 |
| Celecoxib | 12 | $504 | $42 |
| Folic Acid | 32 | $173 | $5 |
| Cyclobenzaprine | 14 | $171 | $12 |
2021: 15 drugs
| Enbrel Sureclick | 12 | $126,679 | $10,557 |
| Humira(Cf) | 18 | $118,491 | $6,583 |
| Orencia Clickject | 15 | $116,436 | $7,762 |
| Xeljanz Xr | 17 | $108,017 | $6,354 |
| Hydroxychloroquine Sulfate | 117 | $12,066 | $103 |
| Methotrexate | 109 | $8,692 | $80 |
| Leflunomide | 15 | $3,667 | $244 |
| Sulfasalazine | 42 | $1,735 | $41 |
| Colchicine | 13 | $1,565 | $120 |
| Prednisone | 102 | $1,458 | $14 |
| Alendronate | 63 | $855 | $14 |
| Diclofenac | 21 | $736 | $35 |
| Allopurinol | 27 | $476 | $18 |
| Gabapentin | 15 | $298 | $20 |
| Folic Acid | 14 | $77 | $6 |
2020: 20 drugs
| Enbrel Sureclick | 15 | $125,539 | $8,369 |
| Humira(Cf) | 20 | $121,806 | $6,090 |
| Xeljanz Xr | 20 | $94,298 | $4,715 |
| Prolia | 29 | $37,125 | $1,280 |
| Hydroxychloroquine Sulfate | 117 | $12,483 | $107 |
| Methotrexate | 184 | $12,447 | $68 |
| Leflunomide | 39 | $8,184 | $210 |
| Sulfasalazine | 85 | $4,614 | $54 |
| Colchicine | 18 | $2,642 | $147 |
| Prednisone | 152 | $2,088 | $14 |
| Pregabalin | 14 | $1,525 | $109 |
| Diclofenac | 31 | $1,221 | $39 |
| Alendronate | 81 | $1,086 | $13 |
| Gabapentin | 50 | $1,055 | $21 |
| Azathioprine | 14 | $834 | $60 |
| Duloxetine | 15 | $632 | $42 |
| Allopurinol | 22 | $439 | $20 |
| Ibuprofen | 13 | $252 | $19 |
| Methotrexate | 12 | $174 | $14 |
| Meloxicam | 11 | $77 | $7 |
2019: 11 drugs
| Humira | 24 | $133,631 | $5,568 |
| Enbrel | 16 | $68,058 | $4,254 |
| Humira | 12 | $48,790 | $4,066 |
| Xeljanz | 11 | $16,612 | $1,510 |
| Leflunomide | 32 | $4,895 | $153 |
| Hydroxychloroquine Sulfate | 48 | $4,256 | $89 |
| Methotrexate | 94 | $3,669 | $39 |
| Sulfasalazine | 28 | $1,808 | $65 |
| Diclofenac | 16 | $1,551 | $97 |
| Prednisone | 57 | $1,207 | $21 |
| Alendronate | 23 | $271 | $12 |
2018: 2 drugs
| Methotrexate | 11 | $1,548 | $141 |
| Prednisone | 13 | $265 | $20 |
2017: 1 drug
| Methotrexate | 16 | $2,067 | $129 |
Money from drug and device companies
$25 in 2025
| 2025 | 1 | 1 | None | $25 |
| 2024 | 1 | 1 | None | $28 |
| 2023 | 2 | 2 | None | $46 |
| 2022 | 5 | 7 | None | $156 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $25 | 1 payment
|
See the published payment
| Abbvie | Meals · 2025-09-30 | Skyrizi | $25 |
See earlier years (2024, 2023, 2022)
2024: $28
| Pfizer | Xeljanz | $28 | 1 payment
|
2023: $46
| AbbVie | Rinvoq | $29 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Orencia | $17 | 1 payment
|
2022: $156
| Janssen Biotech | Remicade | $54 | 2 payments
|
| Pfizer | Xeljanz | $41 | 2 payments
|
| Abbvie | Rinvoq | $23 | 1 payment
|
| Novo Nordisk | Rybelsus | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $18 | 1 payment
|
Professional record
- NPI
- 1982048112
- Licence
- CA A133863California A133863: Current · expires 2028-09-30
- Trained
- University of California, San Francisco School of Medicine, 2013
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Student in a training program (390200000X)
- Mailing address
- Po Box 35380, Las Vegas, NV, 89133
- NPI first listed
- 2013-04-18
- NPI last updated
- 2026-02-23
- NPI record certified
- 2026-02-23
This is when the NPI record was last certified, not a medical board exam.